Highlights and Quick Summary
- R&D Expenses for the quarter ending November 30, 2022 was $1.77 Million (a -5.29% decrease compared to previous quarter)
- Year-over-year quarterly R&D Expenses increased by 89.94%
- Annual R&D Expenses for 2022 was $4.69 Million (a 71.19% increase from previous year)
- Annual R&D Expenses for 2021 was $2.74 Million (a 182.66% increase from previous year)
- Annual R&D Expenses for 2020 was $969 Thousand (a 215.01% increase from previous year)
- Twelve month R&D Expenses ending November 30, 2022 was $5.65 Million (a 20.5% increase compared to previous quarter)
- Twelve month trailing R&D Expenses increased by 66.85% year-over-year
Trailing R&D Expenses for the last four month:
30 Nov '22 | 31 Aug '22 | 31 May '22 | 28 Feb '22 |
---|---|---|---|
$5.65 Million | $4.69 Million | $3.73 Million | $3.39 Million |
Visit stockrow.com/OGI
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical R&D Expenses of Organigram Holdings Inc.
Most recent R&D Expensesof OGI including historical data for past 10 years.Interactive Chart of R&D Expenses of Organigram Holdings Inc.
Organigram Holdings Inc. R&D Expenses for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2022 | $1.77 | $1.87 | $1.08 | $0.93 | $4.69 |
2021 | $0.81 | $0.91 | $0.74 | $0.62 | $2.74 |
2020 | $0.48 | $0.28 | $0.13 | $0.36 | $0.97 |
2019 | – | – | – | – | $0.31 |
Business Profile of Organigram Holdings Inc.
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic